Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF)
| Previous Close | 51.60 |
| Open | 51.60 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 51.60 - 51.60 |
| 52 Week Range | 40.93 - 51.98 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | 11.564B |
| Beta (5Y Monthly) | 0.36 |
| PE Ratio (TTM) | 26.06 |
| EPS (TTM) | 1.98 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.37 (2.65%) |
| Ex-Dividend Date | May 20, 2024 |
| 1y Target Est | N/A |
BloombergCVC Explores Options for €11 Billion Drugmaker Recordati
(Bloomberg) -- CVC Capital Partners is exploring options for its controlling stake in Italian drugmaker Recordati SpA, according to people familiar with the matter.Most Read from BloombergTaylor Swift Is Proof That How We Critique Music Is BrokenBiden’s Gains Against Trump Vanish on Deep Economic Pessimism, Poll ShowsBiden’s New Chopper Is Demoted After Scorching White House LawnTesla Soars as Musk’s Cheaper EVs Calm Fears Over StrategyThe buyout firm is working with advisers and is in the early
- Reuters
CVC explores options for Italy's Recordati, Bloomberg News reports
CVC and Recordati did not immediately respond to a Reuters request for comments. A CVC-led consortium of investment funds had agreed to buy 51.8% of Recordati in a deal worth about 3 billion euros in 2018. Shares of Recordati have risen about 7.7% since the beginning of this year, giving the company a market capitalization of about 11 billion euros ($11.77 billion).
- Reuters
UPDATE 1-CVC explores options for Italy's Recordati, Bloomberg News reports
CVC Capital Partners is exploring options for its controlling stake in Italian pharmaceutical group Recordati SpA, Bloomberg News reported on Tuesday, citing people familiar with the matter. CVC and Recordati did not immediately respond to a Reuters request for comments. A CVC-led consortium of investment funds had agreed to buy 51.8% of Recordati in a deal worth about 3 billion euros in 2018.
